In late April, Taiwan’s Ministry of Health and Welfare formally promulgated amendments to Taiwan’s Drug Reimbursement Benefits and Payment Standards of the National Health Insurance and Drug Price Adjustment Guidelines. This is part of the general effort of the National Health Insurance Administration (NHIA) to improve drug supply resilience against international supply chain tensions and increasing production expenses.
Drastic changes include a dual review process and a proactive drug listing scheme for insurers to speed up the listing of breakthrough drugs. New drugs developed and put on the market within two years in one of the world’s top ten most developed countries, or older novel chemical entities newly manufactured domestically, can get pricing equivalent to new-to-market drugs in Taiwan.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.